Abstract: Novel bispidine-based compounds including at least an optionally substituted ethanoic acid moiety at the N7-position of the bispidine scaffold, these bispidine-based compounds representing metal chelating ligands able to form metallic complexes having good properties in terms of relaxivity and stability, to complexes including a metal ion complexed with these bispidine-based compounds, and to the use of these bispidine-based compounds in the field of medical imaging or therapy, and more specifically MRI (magnetic resonance imaging) contrast agents and/or nuclear imaging agents for PET (positron emission tomography) and/or SPECT (single photon emission tomography).

Abstract: The present invention relates to particles, useful for drug release detection, comprising: at least one luminescent metal complex of formula [Ln].[L], wherein: Ln is a lanthanide ion, L is an organic ligand comprising a hydrophilic unit with at least 6 chelating groups chosen from the group consisting of hydroxyl, carboxyl, optionally in the carboxylate form, carbonyl, ether, phosphonate, phosphinate, thiolate, amino and imino functions, and at least one drug comprising a conjugated aromatic system, wherein said drug is not covalently bonded to the metal complex, said particle having a size comprised from 3 nm to 2000 nm, and wherein the distribution of the metal complex and the drug within the particle is such that the mean distance between a drug molecule and a metal complex is less than 15 nm.

Abstract: The invention relates to a novel class of ligands, complexes comprising such ligands and a metal ion, and adducts of these metal complexes and a macromolecule. Pharmaceutical compositions and methods of making and using the ligand-metal complexes are also described. The invention also relates to the use of macromolecular adducts for enhancement of diagnostic imaging. In particular, the invention relates to (ethylene)-(propylene)-triaminepentaacetic acid (EPTPA) derivatives, a process for their production, and their use for the production of pharmaceutical agents for NMR diagnosis or radiodiagnosis or radiotherapy.